RxDoctor Payments Data

Vinaychandra Patel, MD

Gastroenterology · El Paso, TXNPI 1992797302

Payments from drug & device makers

$25,831in general payments, 2019–2025

Across 467 payments — averaging $55.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$12K
  • Medtronic$6K
  • AbbVie$2K
  • Johnson & Johnson$1K
  • Pfizer$972
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$773
  • plus $3K from 21 others

What the payments were for

  • Speaking & faculty fees$10,76042%
  • Travel & lodging$6913%
  • Food & beverage$8,47233%
  • Education$1701%
  • Other$5,73722%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,831 in reported general payments places this provider in the 80th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$171,670
Medicare patients
736
Services billed
1,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid18$191,809
Humira PenAdalimumab12$78,752
LinzessLinaclotide28$22,477
Ursodiol62$12,196
Mesalamine19$5,896
Omeprazole249$4,408
Dicyclomine Hcl143$3,920
Famotidine142$2,786
Sucralfate19$874
Pantoprazole Sodium62$824
Esomeprazole Magnesium24$726
Spironolactone34$528
Lactulose15$488
Paroxetine Hcl13$252
Furosemide18$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$234$191,80918 claims
AbbVieLinzess$1,908$22,47728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →